Ohio Wesleyan University Student Health Center’s Tuberculosis Assessment

Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following questions:

Have you ever had close contact with persons known or suspected to have active TB disease?  □ Yes  □ No

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, please CIRCLE the country, below)  □ Yes  □ No

Afghanistan  Comoros  Iraq  Namibia  Somalia
Algeria  Congo  Kazakhstan  Nauru  South Africa
Angola  Côte d'Ivoire  Kenya  Nepal  South Sudan
Anguilla  Democratic People's Republic of Korea  Kiribati  New Caledonia  Sri Lanka
Argentina  Democratic Republic of the Congo  Kuwait  Nicaragua  Sudan
Armenia  Djibouti  Kyrgyzstan  Niger  Suriname
Azerbaijan  Lao People's Democratic Republic  Latvia  Nigeria  Swaziland
Bangladesh  Lebanon  Lithuania  Northern Mariana Islands  Syrian Arab Republic
Belarus  Democratic Republic of the Congo  Madagascar  Palau  Tajikistan
Belize  Equatorial Guinea  Malawi  Panama  Thailand
Benin  Ecuador  Malaysia  Papua New Guinea  Timor-Leste
Bhutan  El Salvador  Maldives  Paraguay  Togo
Bolivia (Plurinational State of)  Eritrea  Mauritania  Peru  Tunisia
Bosnia and Herzegovina  Ethiopia  Mauritius  Philippines  Turkmenistan
Botswana  Fiji  Mexico  Portugal  Tuvalu
Brazil  Gabon  Micronesia (Federated States of)  Qatar  Uganda
Brunei Darussalam  Gambia  Marshall Islands  Republic of Korea  Ukraine
Bulgaria  Georgia  Mali  Republic of Moldova  Uruguay
Burkina Faso  Ghana  Mauritania  Romania  Uzbekistan
Burundi  Greenland  Mauritius  Russian Federation  Vanuatu
Cabo Verde  Guam  Mexico  Rwanda  Venezuela (Bolivarian Republic of)
Cambodia  Guatemala  Micronesia (Federated States of)  Sao Tome and Principe  Viet Nam
Cameroon  Guinea  Mongolia  Senegal  Yemen
Central African Republic  Guinea-Bissau  Montenegro  Serbia  Zambia
Chad  Guyana  Morocco  Singapore  Zimbabwe
China  Haiti  Mozambique  Solomon Islands
China, Hong Kong SAR  Honduras
China, Macao SAR  India
Colombia  Indonesia


Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above)  □ Yes  □ No

Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?  □ Yes  □ No

Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?  □ Yes  □ No

Have you ever been a member of any of the following groups that may have an increased incidence of latent M. tuberculosis infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?  □ Yes  □ No

If the answer is YES to any of the above questions, [insert your college/university name] requires that you receive TB testing as soon as possible but at least prior to the start of the subsequent semester).

If the answer to all of the above questions is NO, no further testing or further action is required.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.
Part II. Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

History of a positive TB skin test or IGRA blood test? (If yes, document below)    Yes ____ No _____
History of BCG vaccination? (If yes, consider IGRA if possible.)    Yes ____ No ______

1. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease?    Yes ____ No _____
If No, proceed to 2 or 3
If yes, check below:
- Cough (especially if lasting for 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- Chest pain
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Fever

Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)
(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0”. The TST interpretation should be based on mm of induration as well as risk factors.)**

Date Given: ____/____/____  Date Read: ____/____/____
M     D       Y                  M     D      Y
Result: ________ mm of induration          **Interpretation:  positive____ negative____

Date Given: ____/____/____  Date Read: ____/____/____
M     D       Y                  M     D      Y
Result: ________ mm of induration          **Interpretation:  positive____ negative____

**Interpretation guidelines

>5 mm is positive:
- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

>10 mm is positive:
- Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:
- Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.
3. Interferon Gamma Release Assay (IGRA)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other_____
M      D      Y
Result:  negative___  positive___  indeterminate___  borderline___ (T-Spot only)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other_____
M      D      Y
Result:  negative___  positive___  indeterminate___  borderline___ (T-Spot only)

4. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: ____/____/____   Result: normal____ abnormal_____
M      D      Y

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with *M. tuberculosis* (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunoileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

_____ Student agrees to receive treatment
_____ Student declines treatment at this time

_________________________________________________________          ______________________________
Health Care Professional Signature                                                                                         Date

Please return completed forms to: OWU Student Health Center Stuyvesant Hall
Delaware, OH 43015
Phone (740) 368-3160   Fax (740-368-3166
health@owu.edu